Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;52(4):740-743.
doi: 10.1111/1346-8138.17626. Epub 2025 Jan 16.

Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events

Akiko Sugiyama  1   2 , Atsuko Yano-Takamori  2 , Kaoru Kojima  3 , Haruko Nishie  2 , Miku Nishimura  2 , Tetsuya Hiramoto  3 , Takeshi Nakahara  4
Affiliations

Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events

Akiko Sugiyama et al. J Dermatol. 2025 Apr.

Abstract

Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab. We also found that the score of excoriation on the trunk tended to be higher. These results indicate that patients with mild severity of eruptions on the trunk at initiation could be suitable for nemolizumab therapy, with the potential for long-term continuation with the control of cAEs.

Keywords: AD; EASI; adverse event; interleukin‐31; nemolizumab.

PubMed Disclaimer

References

REFERENCES

    1. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. XCIMA study group anti‐interleukin‐31 receptor an antibody for atopic dermatitis. N Engl J Med. 2017;376:826–835.
    1. Nakashima C, Otsuka A, Kabashima K. Interleukin‐31 and interleukin‐31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27:327–331.
    1. Kim BS. Learning from nemolizumab: a promising therapy for prurigo nodularis. J Allergy Clin Immunol. 2024;153:1548–1549.
    1. Labib A, Vander Does A, Yosipovitch G. Nemolizumab for atopic dermatitis. Drugs Today (Barc). 2022;58:159–173.
    1. Igarashi A, Katsunuma T, Matsumura T, Komazaki H, Nemolizumab‐JP04 Study Group. Efficacy and safety of nemolizumab in pediatric patients aged 6‐12 years with atopic dermatitis with moderate‐to‐severe pruritus: results from a phase III, randomized, double‐blind, placebo‐controlled, multicenter study. Br J Dermatol. 2023;190:20–28.

MeSH terms

Substances

LinkOut - more resources